Clinical Trial

The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 5, 2025 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The study is being conducted to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of XJN010 Nasal Spray in Patients with Parkinson's Disease Experiencing Off Episodes
Trial Details
NCT Number NCT07156773
Lead Sponsor Guangzhou Novaken Pharm Co., Ltd.
Conditions Parkinson Disease
Enrollment 84 participants
Start Date 2025-09-03
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-05